Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 6/20 | 1.00 |
| ▸ | PTPN12 | Q05209 | 5/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 1.00 |
| ▸ | PTPN22 | Q9Y2R2 | 5/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.77 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17240991 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008709 | 0.88 | PTPN12 (1.00) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008726 | 0.83 | PTPN12 (0.90) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12328428 | 0.82 | MAPT (0.74) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008712 | 0.81 | PTPN12 (0.86) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008937 | 0.81 | POLB (0.90) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL13417308 | 0.79 | KMT2A (1.00) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008735 | 0.77 | PTPN12 (1.00) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008563 | 0.77 | GPR35 (0.76) | KMT2AMEN1MAPTPOLBPTPN12 | |
| SCHEMBL12008589 | 0.76 | MEN1 (0.76) | KMT2AMEN1MAPTPOLBPTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10473669-B2 | Methods for treating inflammatory bowel disease | NOGRA PHARMA LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| EP-3355896-A2 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | Nogra Pharma Limited (IE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180180630-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| EP-3237018-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | Celgene Alpine Investment Company II, LLC (BM) | 2017-11-01 | — | — | EP | disclosed |
| EP-3140658-A2 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Nogra Pharma Limited (IE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016105516-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015169966-A2 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | SMAD3, SMAD2, SOST | KMT2A 3254/4885MEN1 4074/4885MAPT 3049/4885 |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | SMAD3, SMAD2, SOST | KMT2A 3335/4885MEN1 4411/4885MAPT 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.